GeoVax proceeds with trial of investigational HIV vaccine

01/14/2013 | Pharmaceutical Business Review Online

GeoVax Labs has completed enrollment for a Phase I/II study assessing the safety and immunogenicity of its experimental therapeutic DNA/MVA vaccine in HIV-positive patients whose infections can be controlled with oral drugs. The company could proceed to an early-stage trial of the vaccine with conventional care in young adults, Chief Scientific Officer Harriet Robinson said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC